Navigating the Latest Evidence and Strategies for Renal Risk Reduction in T2D
Webinar/Online
Friday, November 1, 2024 at 1:00pm ET - 2:00pm ET
This event has ended.
Posted by Nurse Practitioner Events
Info
Topic
Join 2 expert faculty in this live webinar as they provide a comprehensive review of the renal benefits associated with GLP-1 receptor agonists. Participants will explore the latest clinical data, proposed mechanisms, and evidence-based guidelines to optimize glycemic control and improve cardiorenal outcomes in patients with type 2 diabetes and chronic kidney disease.
Credits Offered
This event offers
1.0 contact hour
to attendees.
Accreditation Info:
ANCC.
Additional Information
Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with CKD and T2D.
Target Audience
This program is intended for nephrologists, endocrinologists, primary care physicians, nurse practitioners, physician associates, and other healthcare professionals who manage patients with type 2 diabetes (T2D) and chronic kidney disease (CKD).
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the proposed mechanisms of renal benefits with GLP-1 RAs
- Evaluate the latest efficacy and safety data for GLP-1 RAs in patients with T2D and CKD
- Incorporate into practice the latest guidelines and evidence-based therapies to achieve glycemic goals and improve cardiorenal outcomes in patients with T2D and CKD
Virtual Event Access Instructions
Video chat service
Live WebcastURL
https://clinicaloptions.com/events/renal-risk-reduction-in-t2d/renal-risk-reduction-in-t2d/14306-18182Speakers
Norman S. Wilker Professor of Medicine
Director, Nephrology Division
New York University Grossman School of Medicine
New York, New York
Professor of Medicine Division of Endocrinology Department of Medicine Duke Clinical Research Institute Duke University Medical Center Durham, North Carolina